Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report

Satoh,Hiroaki; Takayashiki,Norio; Shiozawa,Toshihiro; Miyazaki,Kunihiko; Ohara,Gen; Kagohashi,Katsunori; Kurishima,Koichi; Sugita,Shintaro; Aoyama,Tomoyuki; Hasegawa,Tadashi; Hizawa,Nobuyuki

doi:10.3892/etm.2015.2308

Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report

Authors:
- Hiroaki Satoh
- Norio Takayashiki
- Toshihiro Shiozawa
- Kunihiko Miyazaki
- Gen Ohara
- Katsunori Kagohashi
- Koichi Kurishima
- Shintaro Sugita
- Tomoyuki Aoyama
- Tadashi Hasegawa
- Nobuyuki Hizawa
View Affiliations

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan, Division of Pathology, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 210-0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060‑8556, Japan
Published online on: February 24, 2015 https://doi.org/10.3892/etm.2015.2308
Pages: 1947-1949

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pulmonary synovial sarcoma is a rare but aggressive disease. The present study describes the case of a 68‑year‑old female with pulmonary synovial sarcoma. The patient was mistakenly treated for small cell lung cancer due to false‑positive staining for synaptophysin and cluster of differentiation 56. Despite severe myelotoxicity, platinum‑containing chemotherapies (cisplatin plus irinotecan and carboplatin plus etoposide) were not effective. As a third‑line therapy, the patient received amrubicin (AMR) monotherapy. A partial response was achieved, and the patient was able to undertake ordinary daily life at home for 13 months from the initiation of AMR chemotherapy. Due to the atypical clinical condition and unusual response to chemotherapy in this patient, the pathological examination was repeated. The SS18 split‑signal was detected in fluorescence in situ hybridization analysis. From these results, the tumor was diagnosed as a monophasic synovial sarcoma. To the best of our knowledge, this is the first case of a patient with pulmonary synovial sarcoma who underwent successful treatment with AMR. The present case could demonstrate a specific chemosensitivity of such a rare tumor.

View Figures

View References

1	Siegel HJ, Sessions W, Casillas MA Jr, et al: Synovial sarcoma: clinicopathologic features, treatment, and prognosis. Orthopedics. 30:1020–1025. 2007.PubMed/NCBI
2	Liu CY, Yen CC, Chen WM, et al: Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 17:2102–2111. 2010. View Article : Google Scholar : PubMed/NCBI
3	Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ and Brennan MF: Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 235:424–434. 2002. View Article : Google Scholar : PubMed/NCBI
4	Morrison BA: Soft tissue sarcomas of the extremities. Proc (Bayl Univ Med Cent). 16:285–290. 2003.PubMed/NCBI
5	Kitagawa C, Saka H, Kajikawa S, Mori K, Oki M and Suzuki R: Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial. Cancer Chemother Pharmacol. 69:1379–1385. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zeren H, Moran CA, Suster S, Fishback NF and Koss MN: Primary pulmonary sarcomas with features of monophasic synovial sarcoma: A clinicopathological, immunohistochemical and ultrastructural study of 25 cases. Hum Pathol. 26:474–480. 1995. View Article : Google Scholar : PubMed/NCBI
7	Hartel PH, Fanburg-Smith JC, Frazier AA, et al: Primary pulmonary and mediastinal synovial sarcoma: A clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 20:760–769. 2007. View Article : Google Scholar : PubMed/NCBI
8	Watzka SB, Setinek U, Prosch H and Müller MR: Primary synovial sarcoma of the lung as an incidental finding. Interact Cardiovasc Thorac Surg. 9:1026–1028. 2009. View Article : Google Scholar : PubMed/NCBI
9	Frazier AA, Franks TJ, Pugatch RD and Galvin JR: From the archives of the AFIP: Pleuropulmonary synovial sarcoma. Radiographics. 26:923–940. 2006. View Article : Google Scholar : PubMed/NCBI
10	dos Santos NR, de Bruijn DR and van Kessel AG: Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer. 30:1–14. 2001. View Article : Google Scholar : PubMed/NCBI
11	Miura Y, Keira Y, Ogino J, et al: Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors. Pathol Int. 62:16–27. 2012. View Article : Google Scholar : PubMed/NCBI
12	Cuffe S, Moua T, Summerfield R, Roberts H, Jett J and Shepherd FA: Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol. 6:818–822. 2011. View Article : Google Scholar : PubMed/NCBI
13	Bacha EA, Wright CD, Grillo HC, et al: Surgical treatment of primary pulmonary sarcomas. Eur J Cardiothorac Surg. 15:456–460. 1999. View Article : Google Scholar : PubMed/NCBI
14	Shah CM: Amrubicin: A synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer. Recent Pat Anticancer Drug Discov. 4:241–245. 2009. View Article : Google Scholar : PubMed/NCBI
15	Walczak BE and Irwin RB: Sarcoma chemotherapy. J Am Acad Orthop Surg. 21:480–491. 2013. View Article : Google Scholar : PubMed/NCBI
16	Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
17	Suzuki T, Minamide S, Iwasaki T, Yamamoto H and Kanda H: Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs. 15:219–225. 1997. View Article : Google Scholar : PubMed/NCBI
18	Noda T, Watanabe T, Kohda A, Hosokawa S and Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 16:121–128. 1998. View Article : Google Scholar : PubMed/NCBI
19	Fulbright JM, Huh W, Anderson P and Chandra J: Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr Oncol Rep. 12:411–419. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ogawara D, Fukuda M, Nakamura Y and Kohno S: Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. Cancer Manag Res. 2:191–195. 2010.PubMed/NCBI
21	Onoda S, Masuda N, Seto T, et al: Thoracic Oncology Research Group Study 0301: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
22	Harada T, Oizumi S, Ito K, et al: Hokkaido Lung Cancer Clinical Study Group: A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. Oncologist. 18:439–445. 2013. View Article : Google Scholar : PubMed/NCBI